Advertisement
Research Article Free access | 10.1172/JCI107155
Service de Médecine Interne et d'Investigation Clinique de l'Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
Find articles by Stryckmans, P. in: JCI | PubMed | Google Scholar
Service de Médecine Interne et d'Investigation Clinique de l'Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
Find articles by Manaster, J. in: JCI | PubMed | Google Scholar
Service de Médecine Interne et d'Investigation Clinique de l'Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
Find articles by Lachapelle, F. in: JCI | PubMed | Google Scholar
Service de Médecine Interne et d'Investigation Clinique de l'Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
Find articles by Socqouet, M. in: JCI | PubMed | Google Scholar
Published January 1, 1973 - More info
The leukocytes of 16 adult patients with acute myeloblastic leukemia were studied by autoradiographic methods to elucidate the mode of action of daunomycin.
It was shown that daunomycin, at clinically useful doses, exhibits a cytolytic effect on all leukemic blasts whatever their cell-cycle phase. This cytolytic action affects, however, preferentially S-phase cells.
It was shown also that blasts of patients less sensitive to daunomycin or receiving a lesser dose of the drug are temporarily blocked in G2 phase (delayed mitosis) or in G2 phase (prolonged generation time).
Finally daunomycin appeared to hamper the passage of G2-blocked blasts from the bone marrow to the blood, while G2-phase cells crossed freely.